Plant-based diets may be associated with slower disease progression in men with prostate cancer
1. In a cohort of men with prostate cancer, disease progression was lower in men who had a higher intake...
Urology
Reports of high-impact urology studies by medical professionals
Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with...
Gepotidacin safe and effective for treatment of uncomplicated urinary tract infections
1. Therapeutic response at days 10-13 was greater in the gepotidacin group compared to the nitrofurantoin group across both trials....
Cefepime-taniborbactam is superior to meropenem in treating complicated urinary tract infections
1. In this randomized controlled trial, among hospitalized adults with a complicated urinary tract infection (UTI), cefepime-taniborbactam was superior to...
Testosterone treatment for hypogonadism did not reduce the risk of fractures
1. In this randomized controlled trial, topical testosterone was not superior to placebo in reducing the risk of fractures in...
![Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2016/01/Papillary_renal_cell_carcinoma_-_very_high_mag-350x250.jpg)
Utilizing systematic inflammatory response index to predict metastasis in renal cancer
1. This prospective study found that the Systematic Inflammatory Response Index (SIRI) and Systemic Immune-Inflammation Index (SII), as well as...
Testosterone replacement therapy not associated with prostate cancer risk
1. In a population of men with hypogonadism and PSA concentrations less than 3 ng/mL, patients randomized to receive testosterone...
Treatment of lower urinary tract symptoms in men in primary care using a conservative intervention
1. This randomised control trial demonstrated that a standardised and manualised intervention in primary care showed a sustained reduction in...
Risk of short-term prostate-specific antigen recurrence and failure in patients with prostate cancer
1. For patients with unfavorable nonmetastatic prostate cancer aged above 70 years, PSA levels above 10 ng/mL, and Gleason scores...
Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma
1. Recurrence-free survival was significantly different between the adjuvant everolimus and placebo groups. 2. Grade 3 or higher adverse events...
